SEER, INC. : Results of Operations and Financial Condition (form 8-K)
January 25, 2021 at 04:40 pm
Share
Item 2.02. Results of Operations and Financial Condition.
On January 25, 2021, Seer, Inc. (the "Company") filed a registration statement
on Form S-1 (the "Preliminary Prospectus") with the Securities and Exchange
Commission ("SEC") relating to a proposed public offering of the Company's Class
A common stock (the "Offering"). The Company included the following disclosure
in the Preliminary Prospectus (the "Preliminary Estimate") under the heading
"Recent Developments":
"As of December 31, 2020, our cash, cash equivalents and investments were $431.9
million."
The Preliminary Estimates are not our final cash, cash equivalents and
investments results or a comprehensive statement of our financial results for
the year ended December 31, 2020. We caution that our final results for the year
ended December 31, 2020 that we will file with the SEC could vary significantly
from these Preliminary Estimates as a result of the completion of our customary
year-end closing, review and audit procedures and other developments arising
between now and the time that our financial results for the year ended December
31, 2020 are finalized. The Preliminary Estimates should not be viewed as a
substitute for complete financial statements prepared in accordance with
generally accepted in the United States of America ("GAAP") and they are not
necessarily indicative of the results to be achieved in any future period.
Accordingly, you should not place undue reliance on the Preliminary Estimates.
Item 8.01. Other Events.
On January 25, 2021, the Company issued a press release announcing the
commencement of the Offering. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release, dated January 25, 2021.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
